Skip to main content
KOREA PHARMA Co., Ltd. logo

KOREA PHARMA Co., Ltd. — Investor Relations & Filings

Ticker · 032300 ISIN · KR7032300006 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2022-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 032300

About KOREA PHARMA Co., Ltd.

https://www.koreapharma.co.kr/eng/main/…

KOREA PHARMA Co., Ltd. is a pharmaceutical company established in 1974 that specializes in the development and production of prescription-based medicines. The company has a particular focus on drugs for the Central Nervous System (CNS). Its product portfolio covers a wide range of therapeutic areas, including hepatic, gastrointestinal, antimicrobial, and antihistamine drugs. The company also offers treatments such as amino acids, antibiotics, antidotes, and antiepileptics, aiming to improve and maintain public health through its specialized pharmaceutical products.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, profit) for the fiscal year. While it contains financial data, it is a formal notification of the submission of the audit report to the regulator, rather than the full annual report itself. Under the 'Menu vs Meal' rule, this is a regulatory announcement of the filing of the audit report. FY 2021
2022-03-18 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Korea Pharma (한국파마). It contains the meeting agenda, details on voting procedures, electronic voting instructions, and management information such as director activities and remuneration. This document is a formal proxy statement and meeting notice sent to shareholders to solicit votes for the upcoming AGM. In the context of the provided filing categories, this fits the definition of a Proxy Solicitation & Information Statement.
2022-03-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including the addition/removal of special related parties and new stock collateral contracts. This falls under the category of Major Shareholding Notification (MRQ).
2022-03-07 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company '한국파마'. It details the date, location, and specific agenda items (proposals) for the upcoming meeting, including financial statement approval, director appointments, and remuneration limits. This type of document is sent to shareholders to provide information and request their votes for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2022-03-03 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by Korea Pharma regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and provides details on the meeting date and notice date. Since it is a regulatory notification regarding meeting logistics rather than the AGM presentation materials themselves, and it does not fit into specific categories like proxy solicitation or voting results, it is classified as a general regulatory filing.
2022-03-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure for insiders (directors/executives) to report their shareholdings and changes in ownership. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-03-03 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.